ASH News About Hodgkin’s Lymphoma Drug Brentuximab Vedotin (SGN-35)

I recently ran an article about a promising new lymphoma drug, brentuximab vedotin (SGN-35).  Here are study results, just released to us from the ASH press room about bv:
Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma [Abstract 283]

While 70-80 percent of all newly diagnosed patients with adult Hodgkin lymphoma are typically cured with combination chemotherapy of three or four agents together, there still is a significant number of patients whose disease progresses after initial induction chemotherapy. For these patients, treatment options include additional courses of the same or different chemotherapy regimens followed by an autologous stem cell transplant. However, for patients whose disease returns after an autologous stem cell transplant, there currently are no approved treatment options.